Table 3 TRAEs in the maintenance phase in the intent to treat population related to atezolizumab (n = 38)

From: Induction chemo-immunotherapy followed by chemo-radiotherapy and immunotherapy maintenance in stage III NSCLC (APOLO): a phase 2 trial

TRAE category, n (%)

Any grade

Grade 1–2

Grade 3–4

Anya

17 (44.7)

16 (42.1)

2 (5.3)

Leading to discontinuation of treatment

2 (5.2)

2 (5.2)

0 (0)

Serious

1 (2.6)

0 (0)

1 (2.6)

Treatment-related deaths

0 (0)

0 (0)

0 (0)

  1. TRAE treatment-related adverse events.
  2. aTRAEs reported in more or equal to 10% of patients.
Back to article page